
- /
- Supported exchanges
- / US
- / REPCF.PINK
RepliCel Life Sciences Inc (REPCF PINK) stock market data APIs
RepliCel Life Sciences Inc Financial Data Overview
0913693 B.C. Ltd., a regenerative medicine company, develops autologous cell therapies for the treatment of functional cellular deficits. Its treatments use autologous cell therapy to treat chronic tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company's product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy for aging or sun damaged skin; and RCT-01, a cell therapy for tendon degeneration. It is also developing DermaPrecise, a dermal injection device. 0913693 B.C. Ltd. has a licensing and collaborative agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize programs. The company was formerly known as RepliCel Life Sciences Inc. and changed its name to 0913693 B.C. Ltd. in March 2025. 0913693 B.C. Ltd. is based in Vancouver, Canada.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get RepliCel Life Sciences Inc data using free add-ons & libraries
Get RepliCel Life Sciences Inc Fundamental Data
RepliCel Life Sciences Inc Fundamental data includes:
- Net Revenue: 265 K
- EBITDA: -376 826
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-28
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
RepliCel Life Sciences Inc News

TSX Venture Exchange Stock Maintenance Bulletins
VANCOUVER, BC, Jan. 4, 2023 /CNW/ - TSX VENTURE COMPANIES ELEVATION GOLD MINING CORPORATION ("ELVT.WT") BULLETIN TYPE: Warrant Expiry-Delist BULLETIN DATE: January 4, 2023 TSX Venture Tier 2 Co...


RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration Agreement
MainPointe Deal Positions RepliCel for entry into the U.S. market and significant milestones in Japan VANCOUVER, BC / ACCESSWIRE / January 25, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV...

RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration Agreement
MainPointe Deal Positions RepliCel for entry into the U.S. market and significant milestones in Japan VANCOUVER, BC / ACCESSWIRE / January 25, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV...

RepliCel Announces a Binding Term Sheet For Strategic Investment and U.S. Partnership
Transactionrepresents RepliCel’s entrance into the U.S. market Investment termsminimize dilution and puts RepliCel on-track for US FDA marketing approvalsofthe RepliCel Dermal InjectorProduct Line ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.